Blood pressure drug shows Long-Term safety in rare lung condition

NCT ID NCT02759419

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study followed 18 adults with pulmonary arterial hypertension (PAH) who had already taken riociguat in earlier trials. Researchers wanted to see if the drug remained safe and tolerable over a longer period. The goal was to keep providing treatment until it was no longer helpful or became commercially available.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION, PULMONARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Study site

Besançon, 25030, France
Study site

Brest, F-29609, France
Study site

Le Kremlin-Bicêtre, 94275, France
Study site

Lille, 59037, France
Study site

Rouen, 76031, France
Study site

Seoul, Seoul Teugbyeolsi, 03722, South Korea
Study site

Seoul, Seoul Teugbyeolsi, 05505, South Korea
Study site

Seoul, Seoul Teugbyeolsi, 3080, South Korea
Study site

Seoul, 06351, South Korea

Conditions

Explore the condition pages connected to this study.

HYPERTENSION, PULMONARY